<span item_type="fundamental" item_id="19a2a422491207f5f0ab8d3f85a6e37d" counter_id="ST/US/RFL" env="prod"></span><span item_type="announcement" item_id="592584870466159233" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 240 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.19.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -10.38 M.</p><p></p><h3>Net Loss</h3><ul><li>Net loss attributable to Rafael Holdings was - $9.8 million, or - $0.19 per share, compared to a net loss of - $9.0 million, or - $0.37 per share in the same period last year. The increase in net loss is due to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>Research and Development Expenses</h3><ul><li>Research and development expenses were $7.5 million for the three months ended October 31, 2025, compared to $1.3 million in the same period last year. The increase is related to the inclusion of Cyclo’s spending following the March 2025 acquisition.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>General and Administrative Expenses</h3><ul><li>General and administrative expenses were $2.8 million for the three months ended October 31, 2025, compared to $2.5 million in the same period last year. The increase is related to the inclusion of Cyclo’s expenses following the March 2025 acquisition.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>Cash and Cash Equivalents</h3><ul><li>As of October 31, 2025, Rafael Holdings had cash and cash equivalents of $45.5 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>Revenue</h3><ul><li>Revenue for the three months ended October 31, 2025, was $240 thousand, compared to $128 thousand in the same period last year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>Operating Loss</h3><ul><li>Operating loss for the three months ended October 31, 2025, was - $10.1 million, compared to - $3.8 million in the same period last year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul><h3>Forward-Looking Statements</h3><ul><li>Rafael Holdings is optimistic about the progress of their pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. The Data Monitoring Committee recommended continuing the study after reviewing prespecified safety and efficacy data at 48 weeks.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm"></span></li></ul>

Rafael-B | 8-K: FY2026 Q1 Revenue: USD 240 K